Kantesti — Medical-Grade AI Blood Test Analyzer

The laboratory profile for this 31-year-old male demonstrates a state of borderline dyslipidemia characterized by elevated Total Cholesterol (218 mg/dL, exceeding the 200 mg/dL threshold) and LDL-C (142 mg/dL, exceeding the 130 mg/dL target), alongside mild hypertriglyceridemia (156 mg/dL, slightly above the 150 mg/dL limit). Glycemic markers remain within normal limits (fasting glucose 98 mg/dL, HbA1c 5.3%), effectively ruling out current diabetes mellitus or overt prediabetes.

Hematological parameters are entirely within reference ranges, with Hemoglobin (14.8 g/dL) and MCV (87.8 fl) indicating normocytic, normochromic status, effectively excluding common anemias. Hepatic enzymes (AST 28 U/l, ALT 32 U/l, GGT 38 U/l) and renal function (Creatinine 1.05 mg/dL, GFR 92 ml/min) are within normal physiological limits, suggesting no evidence of active hepatobiliary or renal pathology.

A notable deficiency is identified in Vitamin D (25-OH) levels at 24.5 ng/ml, which falls below the optimal range of 30.0-70.0 ng/ml. This insufficiency is a common clinical finding that may impact bone mineral density and immune function, requiring targeted supplementation and lifestyle adjustment to reach the sufficiency threshold.

This analysis serves to quantify the patient's cardiovascular risk profile and metabolic health status. By evaluating the lipid triad (Total Cholesterol, LDL-C, Triglycerides) against the Framingham Risk Score framework, we can determine the necessity for early lifestyle intervention to prevent the progression of subclinical atherosclerosis.

The assessment of Vitamin D status is critical for long-term musculoskeletal health and metabolic homeostasis. Given the patient's age of 31, addressing these sub-optimal levels now is essential to mitigate the risk of secondary hyperparathyroidism and potential long-term impacts on bone mineral density.

The patient exhibits a lipid profile consistent with Hyperlipidemia Type IIa, characterized by isolated elevation of LDL-C (142 mg/dL) and Total Cholesterol (218 mg/dL). While HDL-C (52 mg/dL) is protective, the LDL/HDL ratio of 2.73 and the non-HDL cholesterol of 166 mg/dL suggest a moderate risk for future cardiovascular events if left unmanaged.

The patient's glycemic status is optimal, with HbA1c at 5.3% and fasting glucose at 98 mg/dL. These values are well below the ADA diagnostic criteria for prediabetes, indicating robust insulin sensitivity and normal beta-cell function at this time.

A notable deficiency is identified in Vitamin D (25-OH) levels at 24.5 ng/ml, which falls below the optimal range of 30.0-70.0 ng/ml. This insufficiency is a common clinical finding that may impact bone mineral density and immune function.

Vitamin D insufficiency (24.5 ng/ml) is the primary nutritional finding. Levels below 30 ng/ml are associated with impaired calcium absorption and may lead to a compensatory increase in parathyroid hormone, which can negatively affect bone turnover rates over time.

The mild hypertriglyceridemia (156 mg/dL) is borderline and likely diet-related. Given the patient's age, this finding warrants a review of dietary intake, specifically focusing on refined carbohydrates and alcohol consumption, which are known to influence triglyceride synthesis in the liver.

The normal GFR (92 ml/min) and creatinine (1.05 mg/dl) confirm healthy renal filtration capacity. This is a positive prognostic indicator, as it suggests that the current lipid profile has not yet induced any secondary renal microvascular damage.

The lipid pattern (LDL-C 142 mg/dL, TG 156 mg/dL) suggests a potential early stage of metabolic dysregulation. While not meeting the full criteria for Metabolic Syndrome, the trend toward elevated triglycerides and LDL-C requires monitoring to prevent the development of insulin resistance.

The correlation between normal fasting glucose (98 mg/dL) and normal HbA1c (5.3%) confirms the absence of glycemic variability. This is a strong indicator that the patient's current lipid elevation is likely driven by dietary factors rather than insulin resistance.

The TSH level of 2.14 mU/l is within the optimal range (0.5-2.5 mU/l), suggesting normal thyroid function. This rules out subclinical hypothyroidism as a potential contributor to the patient's lipid profile or fatigue.

The primary risk factor is Hyperlipidemia (LDL-C 142 mg/dL), which increases the 10-year ASCVD risk. Based on the ASCVD risk calculator for a 31-year-old male, the absolute risk is currently low, but the lifetime risk is elevated due to the early onset of lipid abnormalities.

Vitamin D insufficiency (24.5 ng/ml) poses a risk for suboptimal bone health and potential immune system modulation. Without correction, this may lead to long-term deficiencies in calcium homeostasis.

Systemic inflammatory markers, specifically CRP at 1.8 mg/L, are within the low-risk category (<2.0 mg/L) per AHA/CDC guidelines. This indicates that the current lipid elevation is not yet driving significant systemic inflammation, providing a favorable window for non-pharmacological intervention.

The patient is a 31-year-old male with borderline hyperlipidemia and Vitamin D insufficiency. Metabolic and hematological parameters are otherwise within normal limits.

The findings indicate a low immediate risk for cardiovascular disease, but highlight the importance of early intervention to manage lifetime risk.

The overall health status is favorable, with no evidence of chronic disease, providing an excellent opportunity for preventative health measures.

Next Steps: Focus on dietary optimization and regular physical activity to lower LDL-C and triglycerides. Begin Vitamin D supplementation. Schedule a follow-up laboratory assessment in 3 months to monitor progress.

Repeat lipid panel in 3 months to monitor the effectiveness of dietary changes on LDL-C and triglyceride levels.

Follow-up serum 25-OH Vitamin D levels in 3 months to ensure the efficacy of the supplementation regimen.

Consider a baseline cardiovascular risk assessment, including blood pressure monitoring, to be integrated into the next annual physical examination.

Consultation with a primary care physician is advised to determine the appropriate dosage for Vitamin D supplementation.